Apidra insulin glulisine: Phase IV data

Data from the open-label, U.S. Phase IV RABBIT-2 Surgery trial in 211 Type II diabetics undergoing general surgery showed that a significantly higher proportion of patients receiving daily Lantus insulin glargine plus Apidra insulin glulisine injections before meals had improved glycemic control as measured by blood glucose levels of <70 mg/dL vs. patients receiving regular insulin per sliding scale (23.1% vs. 4.7%, p<0.001). Lantus plus Apidra also significantly reduced the frequency of the composite of postoperative complications vs. sliding scale insulin (8.6% vs. 24.3%, p=0.003). Specifically, the combination therapy significantly reduced wound infection (2.9% vs. 10.3%, p=0.05), and non-significantly reduced pneumonia (0% vs. 2.8%, p=0.247) and acute renal failure (3.8% vs. 10.3%, p=0.106) vs. sliding scale insulin. ...